使用生物信息学研究TIGD1在肺癌中的生物标志物潜力和分子标
Merve Gülsen Bal Albayrak1, Tuğcan Korak1, Murat Kasap1
1Department of Medical Biology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkiye.
Turkish journal of medical sciences
|December 30, 2024
概括
这项研究揭示了TIGD1在肺癌中的功能,确定了参与癌症进展的关键基因和途径. 这些发现突出了TIGD1作为肺状细胞癌 (LUSC) 的潜在生物标志物和治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 肺癌,特别是肺状细胞癌 (LUSC),尽管是癌症死亡的主要原因,但治疗选择有限.
- 可转移元素及其蛋白质,如TIGD1,与癌症有关,但TIGD1在LUSC中的功能尚不清楚.
研究的目的:
- 为了阐明TIGD1在肺癌中的生物功能.
- 为了确定TIGD1相关的通路和相互作用的蛋白质.
- 探索TIGD1作为LUSC治疗标和生物标记物的潜力.
主要方法:
- 使用微阵列数据 (GSE229260) 和 GEO2R.使用TIGD1沉默的A549细胞的差异基因表达分析.
- 路径丰富分析 (KEGG) 和蛋白质与蛋白质相互作用 (PPI) 网络构建 (STRING,Cytoscape).
- 枢纽基因的识别和功能分析,包括使用ESTIMATE算法评估免疫和 stromal 评分.
主要成果:
- 在TIGD1沉默细胞中发现了13个上调和1个下调的差异表达基因 (DEG).
- 与TIGD1相关的DEGs参与PI3K/AKT,FOXO和p53信号通路.
- 关键的枢纽基因 (AKT1,BRAF,SRC,GAPDH,CCND1,CDKN2A,CTNNB1,KRAS,MYC,TP53) 调节细胞增殖和细胞亡,并与免疫/脑膜组件负相关.
结论:
- TIGD1在肺癌中发挥着重要作用,影响关键信号通路.
- 已识别的枢纽基因及其通路为LUSC提供了潜在的治疗点.
- TIGD1表达和相关的枢纽基因可能成为肺癌治疗的宝贵生物标志物.
相关概念视频
lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


